secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0000950170-23-041274
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amylyx Q2 product revenue $98.2M, net income $22.1M; CHMP re-examining MAA
--------------------------------------------------------------------------

- Net product revenue $98.2M in Q2 2023 (up from $71.4M in Q1); net income $22.1M ($0.31 diluted EPS).
- Cash, equivalents and short-term investments $357.3M at June 30, 2023.
- Phase 3 ORION trial of AMX0035 for PSP to start by year-end; ~600 participants planned.
- CHMP re-examining negative opinion on AMX0035 MAA for ALS; final opinion expected fall 2023.
- Five Canadian provinces now reimburse ALBRIOZA; broad public coverage expected by end of August.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000095017023041274/0000950170-23-041274-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000095017023041274/amlx-20230810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-041274

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer